Brookline Capital Management Analyst Recommendations & Stock Picks

Name: Community Performance Rating
Item: Brookline Capital Management
Rating: 2.1
Author: MarketBeat

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Brookline Capital Management. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Brookline Capital Management.

Company	Date	Action	Brokerage	Rating	Price Target	Impact on Price
ATE Antibe Therapeutics	6/3/2021	Reiterated by	Brookline Capital Management	Buy		N/A
ATBPF Antibe Therapeutics	6/3/2021	Reiterated by	Brookline Capital Management	Buy		Medium
MNPR Monopar Therapeutics	5/25/2021	Reiterated by	Brookline Capital Management	Buy		Medium
SQZ SQZ Biotechnologies	3/30/2021	Reiterated by	Brookline Capital Management	Buy		N/A
ONCT Oncternal Therapeutics	3/30/2021	Reiterated by	Brookline Capital Management	Buy	$16.00	High
NMTR 9 Meters Biopharma	3/25/2021	Reiterated by	Brookline Capital Management	Buy		High
NLSP NLS Pharmaceutics	3/12/2021	Initiated by	Brookline Capital Management	Buy	$12.00	High
CLBS Caladrius Biosciences	3/3/2021	Target Raised by	Brookline Capital Management	Buy	$7.00 -> $10.00	High
MRNA Moderna	2/26/2021	Target Raised by	Brookline Capital Management	Buy	$180.00 -> $205.00	Low
CNSP CNS Pharmaceuticals	2/2/2021	Initiated by	Brookline Capital Management	Buy	$10.00	Low

XFOR X4 Pharmaceuticals	12/17/2020	Initiated by	Brookline Capital Management	Buy	$21.00	High
VERU Veru	12/14/2020	Target Raised by	Brookline Capital Management		$13.00 -> $17.00	High
SYRS Syros Pharmaceuticals	11/10/2020	Initiated by	Brookline Capital Management	Buy	$19.00	Low
CTIC CTI BioPharma	10/23/2020	Initiated by	Brookline Capital Management	Buy	$7.00	Medium
ECOR electroCore	10/23/2020	Initiated by	Brookline Capital Management	Buy	$5.00	Low
AWH Aspira Women's Health	10/14/2020	Reiterated by	Brookline Capital Management	Buy		High
MEIP MEI Pharma	10/12/2020	Reiterated by	Brookline Capital Management	Buy		Medium
DMTK DermTech	9/11/2020	Initiated by	Brookline Capital Management	Buy		High
CNST Constellation Pharmaceuticals	9/3/2020	Initiated by	Brookline Capital Management	Buy	$33.00	Low
MDNA Medicenna Therapeutics	8/24/2020	Reiterated by	Brookline Capital Management	Buy		Medium
FBRX Forte Biosciences	8/28/2020	Initiated by	Brookline Capital Management	Buy	$90.00	Low
HUGE FSD Pharma	8/20/2020	Reiterated by	Brookline Capital Management	Buy		Low
HUGE FSD Pharma	8/20/2020	Initiated by	Brookline Capital Management	Buy	$11.00	N/A
KURA Kura Oncology	8/16/2020	Reiterated by	Brookline Capital Management	Buy		Low
NMTR 9 Meters Biopharma	8/18/2020	Initiated by	Brookline Capital Management	Buy	$5.00	High
VERU Veru	8/14/2020	Reiterated by	Brookline Capital Management	Buy		Low
ARCT Arcturus Therapeutics	8/11/2020	Reiterated by	Brookline Capital Management	Buy		Low
ATE Antibe Therapeutics	7/15/2020	Reiterated by	Brookline Capital Management	Buy		N/A
MRNA Moderna	7/13/2020	Reiterated by	Brookline Capital Management	Buy	$95.00	High
ASRT Assertio	6/3/2020	Initiated by	Brookline Capital Management	Buy	$3.50	Low
CWBR CohBar	5/27/2020	Reiterated by	Brookline Capital Management	Buy		Medium
CWBR CohBar	5/28/2020	Initiated by	Brookline Capital Management	Buy		N/A
CLBS Caladrius Biosciences	5/25/2020	Initiated by	Brookline Capital Management	Buy	$7.00	High
CYCC Cyclacel Pharmaceuticals	5/19/2020	Initiated by	Brookline Capital Management	Buy	$22.00	High
BIOC Biocept	5/14/2020	Initiated by	Brookline Capital Management	Buy		High
OTLK Outlook Therapeutics	5/5/2020	Initiated by	Brookline Capital Management	Buy		High
DARE Daré Bioscience	4/28/2020	Initiated by	Brookline Capital Management	Buy	$7.50	High
BLPH Bellerophon Therapeutics	4/14/2020	Initiated by	Brookline Capital Management	Buy	$35.00	Low
EDSA Edesa Biotech	3/30/2020	Initiated by	Brookline Capital Management	Buy	$10.00	High
CLPT ClearPoint Neuro	3/11/2020	Reiterated by	Brookline Capital Management	Buy		High
ARMP Armata Pharmaceuticals	3/13/2020	Reiterated by	Brookline Capital Management	Buy		High
CLPT ClearPoint Neuro	3/12/2020	Initiated by	Brookline Capital Management	Buy	$15.00	N/A
MNPR Monopar Therapeutics	2/19/2020	Initiated by	Brookline Capital Management	Buy	$42.00	High
BCDA BioCardia	11/26/2019	Reiterated by	Brookline Capital Management	Buy		Low
BCDA BioCardia	11/26/2019	Initiated by	Brookline Capital Management	Buy	$22.00	Low
MDNA Medicenna Therapeutics	11/19/2019	Reiterated by	Brookline Capital Management	Buy	C$4.00	N/A
BCEL Atreca	8/20/2019	Reiterated by	Brookline Capital Management	Buy		High
SCYX SCYNEXIS	8/19/2019	Reiterated by	Brookline Capital Management	Buy		High
VXRT Vaxart	8/15/2019	Initiated by	Brookline Capital Management	Buy	$6.00	Low
CLSN Celsion	7/25/2019	Reiterated by	Brookline Capital Management	Buy		Medium

CHMA Chiasma	7/24/2019	Reiterated by	Brookline Capital Management	Buy		Low
VERU Veru	7/29/2019	Initiated by	Brookline Capital Management	Buy	$12.00	High
HTBX Heat Biologics	7/29/2019	Initiated by	Brookline Capital Management	Buy	$8.00 -> $8.00	High
CLRB Cellectar Biosciences	7/29/2019	Initiated by	Brookline Capital Management	Buy	$6.00 -> $6.00	High
ARCT Arcturus Therapeutics	7/24/2019	Reiterated by	Brookline Capital Management	Buy		High
QBIO Q BioMed	5/10/2019	Reiterated by	Brookline Capital Management	Buy		Low
CHMA Chiasma	2/6/2019	Reiterated by	Brookline Capital Management	Buy		Low
SCYX SCYNEXIS	1/4/2019	Reiterated by	Brookline Capital Management	Buy		High
CLSN Celsion	11/20/2018	Reiterated by	Brookline Capital Management	Buy		Medium
CLRB Cellectar Biosciences	11/20/2018	Reiterated by	Brookline Capital Management	Buy		Low
ARCT Arcturus Therapeutics	9/27/2018	Reiterated by	Brookline Capital Management	Buy		Low
HTBX Heat Biologics	8/1/2018	Reiterated by	Brookline Capital Management	Buy		Low
TNXP Tonix Pharmaceuticals	7/27/2018	Downgraded by	Brookline Capital Management	Buy -> Hold		Low
TNXP Tonix Pharmaceuticals	5/1/2018	Reiterated by	Brookline Capital Management	Buy		Low

CSV / Excel Export To export this table to CSV or Excel, upgrade to MarketBeat All Access.

MarketBeat Community Rating for Brookline Capital Management

Community Ranking:		2.1 out of 5 ( )
Outperform Votes:		17,732 (Vote Outperform)
Underperform Votes:		24,548 (Vote Underperform)
Total Votes:		42,280

MarketBeat's community ratings are surveys of what our community members think about Brookline Capital Management and other research firms. Vote "Outperform" if you believe Brookline Capital Management's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Brookline Capital Management's recmomendations will underperform the S&P 500 over the long term. You may vote once every thirty days.

See Also:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Brookline Capital Management Analyst Recommendations & Stock Picks

MarketBeat Community Rating for Brookline Capital Management

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources